[English]  [Pусский]  [中文]  
 
ctt-journal > Stankevich et al. abstract

Stankevich et al. abstract

Please cite this article as follows: Stankevich Y, Golovacheva A, Babenko E, Alyansky A, Paina O, Zubarovskaya L, Semenova E, Polintsev D, Kruglyakov P, Afanasyev B. Experience of clinical mesenchymal stem cells (MSCs) usage for prophylaxis and GVHD treatment in patients undergoing allo-HSCT. Cell Ther Transplant. 2008;1:e.000024.01. doi:10.3205/ctt-2008-en-000024.01


Experience of clinical mesenchymal stem cells (MSCs) usage for prophylaxis and GVHD treatment in patients undergoing allo-HSCT

Stankevich Y., Golovacheva A., Babenko E., Alyansky A., Paina O., Zubarovskaya L., Semenova E., Polintsev D., Kruglyakov P., Afanasyev B.
Abstract

Within bone marrow stroma, there exist subsets of nonhematopoietic cells referred to as mesenchymal stem cells (MSCs), or mesenchymal stromal cells. These cells may not only improve HSC engraftment and regeneration of damaged tissues after allogeneic transplantation, but also modulate immune responses in vitro and in vivo. Hence, co-transplantation of allogeneic HSC together with allogeneic MSC hypothetically could provide some beneficial effects, such as enhanced engraftment, acceleration of immune reconstitution, GVHD suppression, and it may be used for GVHD prophylaxis, like as for treatment of severe acute or chronic GVHD. This study shows that more than a half of the patients with steroid-refractory acute GVHD responded to treatment with MSCs. However, further randomized clinical trials are necessary for estimation of therapeutic effect of MSCs in allo-HSCT patients and definition of important and significant factors influenced upon MSCs infusion.

Keywords: hematopoetic stem cell transplantation, acute GVHD, chronic GVHD, mesenchymal stem cell

Please cite this article as follows: Stankevich Y, Golovacheva A, Babenko E, Alyansky A, Paina O, Zubarovskaya L, Semenova E, Polintsev D, Kruglyakov P, Afanasyev B. Experience of clinical mesenchymal stem cells (MSCs) usage for prophylaxis and GVHD treatment in patients undergoing allo-HSCT. Cell Ther Transplant. 2008;1:e.000024.01. doi:10.3205/ctt-2008-en-000024.01

Full text
<-- Previous abstract        Contents        Next abstract -->
<-- Предыдущее резюме        Oглавление        Cледующее резюме -->